Angiogenesis, a key component of cancer, may be driven by angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-2. Haemoxygenase-1 (HO-1), a haemdegrading enzyme, may have alternative roles in angiogenesis. Levels of plasma HO-1 have not been reported in prostate cancer. We tested the hypothesis of abnormal HO-1 in 30 men with early prostate cancer, compared with 22 men with benign prostate disease (BPD) and 26 men free of prostate disease, and that HO-1 levels would correlate with VEGF, angiopoietin-2, von Willebrand factor (vWf, marking endothelial perturbation) and PSA. Plasma HO-1 was twofold higher in prostate cancer than in the two control groups, while vWf, VEGF and PSA were also raised (all Po0.02). In the subjects free of prostate disease and in the BPD groups, HO-1 correlated significantly with VEGF (r40.5, Po0.02) but the correlation in prostate cancer was not significant (r ¼ 0.117, P ¼ 0.537). There were no correlations with PSA or the Gleason stage. We conclude that HO-1 is associated with VEGF in health and BPD, but in the presence of prostate cancer, raised levels of both HO-1 and VEGF fail to correlate. This observation may have implications for the pathogenesis of prostate cancer.
Introduction
Prostate cancer is a major public health problem in the Western world, and the second most common male malignancy in the European Union and North America. Angiogenesis is the driving pathophysiology in the early stage of the disease, and is directed by angiogenic growth factors such as vascular endothelial growth factor (VEGF) and angiopoietin. 1, 2 Haemoxygenase-1 (HO-1) is a haem-degrading enzyme whose products are biliverdin, carbon monoxide and iron. 3 Deficiency of this enzyme leads to severe multi-system disease including vascular damage, as is supported by increased plasma von Willebrand factor (vWf), 4 and it has also been implicated in other models of vascular pathology. [5] [6] [7] Other reports suggest roles for HO-1 in defence from viraemia, from oxidant stress, in inflammation and in cardiovascular disease. 8, 9 Notably, there are several reports linking HO-1 with cancer, possibly via interactions with VEGF, 10, 11 suggesting a role in angiogenesis. 12 Increased expression of HO-1 in prostate tissue and a prostate cancer cell line have been reported 13, 14 but there are no reports of plasma HO-1 in this disease.
We hypothesised first, that early prostate cancer is associated with higher plasma levels of HO-1 when compared with men with benign prostate disease (BPD) and healthy controls free of any prostate disease, and second, that there is a positive relationship between HO-1 and markers of angiogenesis (VEGF, angiopoietin-2), and of endothelial perturbation (vWF). We tested our hypotheses in a simple cross-sectional case-control study of early prostate cancer as this disease is known to be associated with raised markers of angiogenesis and endothelial damage/dysfunction.
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Materials and methods
Subjects
Men with prostate cancer and BPD (BPH or prostatitis), both defined by established clinical, imaging, histological (that is biopsy) and laboratory (that is, PSA) findings, were recruited from urology out-patient clinics. Three men had metastatic bone disease (defined by bone scan) and only one was scheduled for surgery. The median (interquartile range) of the Gleason score of this group was seven (6.0-7.25) (Figure 1) , and the most common treatment plan was for prostatectomy or watchful waiting. The second control group consisted of men attending at the same urology out-patient clinical for non-neoplastic, non-inflammatory bladder/andrology indications. The following demographic and other details (where applicable) were noted in each subject:
age, blood pressure, serum PSA, chemotherapy and other prostate-directed drug therapy (for example, Casodex, Zoladex, Finasteride), and radiotherapy. Exclusion criteria were current or previous cardiovascular disease, other cancer, connective tissue disease, diabetes, advanced renal (creatinine 4200 mmol l À1 ), liver disease (ALT 42 Â normal) and being unable to give consent (for example, lack of interpreter, dementia). Those having had previous surgery, chemotherapy and radiotherapy in the previous 3 months were also excluded. Several men were taking other treatments, for example, ACE-inhibitors, diuretics, calcium channel blockers and paracetamol. These men were not excluded.
Laboratory
Following informed consent, venous blood was obtained into EDTA and full blood count was performed (Bayer Advia 120, Siemens, Newbury, UK). An aliquot was taken and centrifuged at 2500 r.p.m. (1000 g) for 20 min to provide plasma for VEGF, HO-1, vWf and the angiopoietins. Plasma was stored at À70 1C for batch analysis by enzyme-linked immunosorbent assay (VEGF and HO-1: DuoSet R&D Systems, Abingdon, UK; vWf: DakoPatts, Ely, Cambs, UK). All assay have intra assay CVs o5%, interassay CVs o10%.
Power calculation and statistics
We modelled that good data from 20 men with prostate cancer, 20 men with BPD (disease controls) and 20 men free of prostate disease would provide enough power (1-beta ¼ 0.80) for a significant difference of one standard deviation in a normally-distributed one index such as vWf of Po0.05 between the healthy and cancer groups (for example, mean 110 (s.d. 20) versus 130 18 with overall analysis of variance Po0.02). For added confidence, we recruited in excess of this group. Data were subjected to the Anderson-Darling distribution test to direct analysis of variance/Kruskal-Wallis/Tukey's testing used for multiple and sub-group analysis. Data are presented as mean and standard deviation (when data normally distributed) or median and interquartile range (nonnormally distributed). The w 2 -test was used for categorical data, Spearman's method was used for correlations. All analyses were performed on Minitab release 15 (State University, PA, USA).
Results
The three groups were matched for age and blood pressure (Table 1) . Men with prostate cancer had higher levels of serum PSA than the other groups, but also had a lower red blood cell count and a lower platelet count compared with the men free of prostate disease. The vWf, VEGF and HO-1 ( Figure 2 ) were all raised in prostate cancer compared with the two other groups but the difference in angiopoietin-2 was not significant (Table 1) .
In the men free of prostate disease, and in those with BPD, HO-1 correlated significantly with VEGF (r ¼ 0.56, P ¼ 0.003 and r ¼ 0.53, P ¼ 0.011, respectively) ( Figures 3  and 4) . However, in prostate cancer, the HO-1/VEGF correlation was not significant at r ¼ 0.12 P ¼ 0.537 ( Figure 5 ). The correlation between Gleason stage and HO-1 was r ¼ À0.057, P ¼ 0.764, but the correlation between Gleason stage and PSA was r ¼ 0.4 (95% confidence interval 0.047-0.809), P ¼ 0.029. However, correlations were not part of our original hypotheses and so we may not necessarily be powered for them. Indeed, with a small sample size we may be at risk of a false positive, especially in the relationship between PSA and Gleason score. Relationship with VEGF, angiopoietin-2 and von Willebrand factor AD Blann et al
Discussion
Our results support the hypothesis that plasma HO-1 is raised in prostate cancer. We also confirm raised VEGF and vWf in this disease although we failed to find raised angiopoietin-2. [15] [16] [17] Notably, in the two control groups, HO-1 correlated with VEGF but in prostate cancer they failed to correlate.
Despite considerable animal data, wherein there are indications of various roles of HO-1 in cancer and cardiovascular disease, the role of HO-1 in actual human disease is unclear. However, possible roles in different pathophysiology patterns are emerging, such as protection of the endothelium from oxidative stress. 4, 6, 7 HO-1 may also be important in cardiovascular disease and in apoptosis, 5, 9, 19, 20 and there is also evidence that HO-1 may be linked experimentally to angiogenesis via VEGF. [10] [11] [12] 18, 21 It is therefore notable that we report good correlations between HO-1 and VEGF (r40.52) (although we acknowledge the possibility of small number error) in the absence of cancer, but that this correlation in markedly weaker in the presence of cancer (r ¼ 0.12). The reasons for this are unclear although it is tempting to speculate a linked role for HO-1 and VEGF in physiology that is uncoupled in cancer. If so, it follows that raised HO-1 and raised VEGF in prostate cancer are the product of different mechanisms.
HO-1 is primarily thought of as an intracellular enzyme wherein it degrades haem to iron, carbon monoxide and biliverdin, the latter being converted to bilirubin. 3 A possible justification for plasma HO-1 is to degrade plasma haem, possibly resulting from intravascular haemolysis. However, the source of this molecule in the plasma is unclear. Although it may arise from the endothelium, lack of correlation with endothelial marker vWf 22 implies it also arises from other tissues. Raised vWf in prostate cancer (as in many cancers) is an established finding and may reflect endothelial disturbance, which in our study can not due to cytotoxic chemotherapy, 23 as the latter is an exclusion criterion. Therefore raised vWf may reflect a non-specific response to the tumour, or perhaps secretion from para-tumoric endothelial cells, although lack of correlation between vWf and VEGF implies such a disturbance is unrelated to angiogenesis. It has been suggested that raised HO-1 protects the endothelium and other cells from damage. [24] [25] [26] Again, lack of correlation between HO-1 and vascular damage marker vWf 22 fails to support this hypothesis, Relationship with VEGF, angiopoietin-2 and von Willebrand factor AD Blann et al although relatively early prostate cancer may not be the most appropriate model in which to test this hypothesis. Despite small numbers, we conclude that raised plasma HO-1 in prostate cancer is unrelated to plasma markers of angiogenesis and of vascular damage and may therefore reflect a generalised effect of the neoplastic process.
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